Summary
PROTACs represent a new modality that eliminates target proteins by leveraging the cell’s ubiquitin-proteasome system.
Vepdegestrant (VEPPANU) became the first FDA-approved PROTAC therapy in May 2026 for the treatment of ER+/HER2- ESR1-mutated breast cancer, representing a significant milestone for this emerging drug modality.
Key assests set to challenge VEPPANU include Astellas Pharma's Setidegrasib (ASP3082), BeOne Medicines' BGB-16673, Arvinas and Novartis' Luxdegalutamide, Nurix Therapeutics' NX-2127 and NX-5948, C4 Therapeutics' CFT8919, Dialectic Therapeutics' DT2216, and others.
For decades, oncology drug development has followed one cent...
